|
|
|
| Safety study on anti-HIV retrovirus drugs in pregnant female and infants |
| LIU Shuaifeng1 GE Xianmin2 SHEN Zhiyong1 DENG Xiao′e3 WU Yufei1 |
1.AIDS Prevention and Treatment Center, Guangxi Center for Disease Prevention and Control, Guangxi Zhuang Autonomous Region, Nanning 530028, China;
2.the Administration Office, Guangxi Center for Disease Prevention and Control, Guangxi Zhuang Autonomous Region, Nanning 530028, China;
3.Department of Physical Examination, Guangxi Center for Disease Prevention and Control, Guangxi Zhuang Autonomous Region, Nanning 530028, China |
|
|
|
Abstract With the continuous research and development of new anti-HIV retrovirus drugs, the effectiveness and safety of drugs are also improving. However, when they are used as preventive drugs for prevention of mother-to-child transmission of HIV, the physiological changes during pregnancy affect drug absorption, distribution, metabolism and secretion. The toxicity and side effects of drugs would aggravate the influence on pregnant female and infants. Under such circumstances, how to choose safe and effective drugs has always been a key issue in our field of health medicine.
|
|
|
|
|
|
[1] 蔡卫平，陈谐捷，李惠琴，等.国家免费艾滋病抗病毒治疗药物手册[M].4版.北京：人民卫生出版社，2016.
[2] 中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2018版）[J].新发传染病电子杂志，2019，4（2）：65-84.
[3] Christian Hoffmann，Jurgen K. Rockstroh，Bernd Sebastian Kamps.艾滋病诊疗学[M].张福杰等译.北京：人民卫生出版社，2009.
[4] Veroniki AA，Antony J，Straus SE，et al. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children：systematic review and network meta-analysis including different study designs [J]. PLoS One，2018，13（6）：e0198447.
[5] 陈劲峰，郭文卫，钟活麟.高效抗逆转录病毒治疗对HIV阳性孕妇的影响[J].现代诊断与治疗，2013，24（3）：483-485.
[6] 邓小娥，刘帅凤，于丽，等.抗病毒治疗对于HIV阳性产后妇女血常规的影响[J].右江民族医学院学报，2017，39（2）：107-109.
[7] Delicio AM，Lajos GJ，Amaral E，et al. Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil：a cohort study [J]. Reprod Health，2018，15（1）：76.
[8] Smith C，Forster JE，Levin MJ，et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis：a retrospective case review [J]. PLoS One，2015，10（5）：e0127062.
[9] García-Otero L，López M，Gómez O，et al. Zidovudine treatment in HIV-infected pregnant women is associated with fetal cardiac remodeling [J]. AIDS，2016，30（9）：1393-1401.
[10] Sax PE，Callant JE，Klotman PE. Renal safety of tenofovir disoproxil fumarate [J]. Aids Read，2007，17（2）：90-92.
[11] Nachega JB，Uthman OA，Mofenson LM，et al. Safety of TenofovirDisoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants：A Systematic Review and Meta-Analysis [J]. J Acquir Immune Defic Syndr，2017，76（1）：1-12.
[12] Rough K，Seage GR，Williams PL，et al. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine [J]. N Engl J Med，2018，378（17）：1593-1603.
[13] 刘帅凤，邓小娥，于丽，等.76例经艾滋病母婴阻断治疗的HIV阳性孕妇产后的临床体征和免疫功能变化[J].中国艾滋病性病，2015，21（5）：385-391.
[14] Singh A，Hemal A，Agarwal S，et al. A prospective study of haematological changes after switching from stavudine to zidovudine-based antiretroviral treatment in HIV-infected children [J]. Int J STD AIDS，2016，27（13）：1145-1152.
[15] Schalkwijk S，Colbers A，Konopnicki D，et al. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women [J]. AIDS，2016，30（8）：1239-1244.
[16] Fauchet F，Treluyer JM，Préta LH，et al. Population pharmacokinetics of abacavir in pregnant women [J]. Antimicrob Agents Chemother，2014，58（10）：6287-6289.
[17] Floridia M，Pinnetti C，Ravizza M，et al. Brief Report：Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV：Laboratory and Clinical Outcomes in an Observational National Study [J]. J Acquir Immune Defic Syndr，2018，78（1）：99-104.
[18] Benaboud S，Tréluyer JM，Urien S. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women [J]. Antimicrob Agents Chemother，2012，56（2）：776-782.
[19] Delicio AM，Lajos GJ，Amaral E，et al. Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015：a cohort study [J]. BMC Infect Dis，2018，18（1）：485.
[20] Sibiude J, Mandelbrot L, Blanche S, et al. Birth defects and ART in the French perinatal cohort, a prospective exhaustive study among 13,124 live births from 1994 to 2010 [J]. CROI，2013：81.
[21] Watts DH，Huang S，culnane M，et al. Birth defects among a cohortof infants born to HIVinfected women on antiretroviral medication [J]. J Perinat Med，2011，39（2）：163-170．
[22] Martinez de Tejada B，European Pregnancy and Paediatric HIV Cohort Collaboration Study Group. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy：A Multicohort Analysis [J]. J Acquir Immune Defic Syndr，2019，80（3）：316-324.
[23] ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infectedantiretroviral-naive adults （ENCORE1）：A randomised，double-blind，placebo-controlled，non-inferiority trial [J]. Lancet，2014，383（9927）：1474-1482.
[24] Yang SP，Liu WC，Lee KY，et al. Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring [J]. J Int AIDS Soc，2014，17（4 Suppl 3）：19524.
[25] Guo F，ChengX，Hsieh E，et al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study [J]. HIV Med，2018. [Epub ahead of print]
[26] Luther J，Glesby MJ. Dermatologic adverse effects of antiretroviral therapy：recognition and management [J]. Am J Clin Dermatol，2007，8（4）：221-233.
[27] 吴焱.欧盟批准第二种“三合一”抗艾滋病毒药物复合片剂Eviplera [J].上海医药，2012，33（5）：6.
[28] Capetti AF，Cossu MV，Paladini L，et al. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection [J]. Expert Opin Pharmacother，2018，19（1）：65-77.
[29] Tookey PA，Thorne C，van Wyk J，et al. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy：analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland [J]. BMC Infect Dis，2016，16：65.
[30] U.S. Food and Drug Administration. Kaletra (lopinavir/ritonavir) Oral Solution label changes related to toxicity in preterm neonates [J]. Tuberculosis.
[31] Mirochnick M，Nielsen-Saines K，Pilotto JH，et al. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life [J]. Pediatr Infect Dis J，2011，30（9）：769-772.
[32] 郭娜，姜太一，粟斌，等.艾滋病简化抗病毒治疗研究进展[J].中国艾滋病性病，2018，24（7）：749-754.
[33] 洪洲，沈银忠.整合酶抑制剂临床应用专家共识[J].上海预防医学，2018，10：836-843.
[34] Jaworsky D，Thompson C，Yudin MH，et al. Use of newer an-tiretroviral agents，darunavir and etravirine with or withouttraltegravirin pregnancy：a report of two cases [J]. AntiVir Ther，2010，15（4）：677-680.
[35] Bornhede R，Soeria-Atmadja S，Westling K，et al. Dolutegravir in pregnancy-effects on HIV-positive women and their infants [J]. Eur J Clin Microbiol Infect Dis，2018， 37（3）：495-500.
[36] Clarke DF，Penazzato M，Capparelli E，et al. Prevention and treatment of HIV infection in neonates：evidence base for existing WHO dosing recommendations and implementation considerations [J]. Expert Rev Clin Pharmacol，2018，11（1）：83-93. |
|
|
|
